

Angina: A Continued Challenge for the Cardiologist

Bibliography of One Hundred Key Papers

selected by **Kim Fox, MD, FRCP, FESC; Caroline Daly, MRCPI**
Royal Brompton Hospital - London - UK

-
- Alderman EL, Bourassa MG, Cohen LS, et al.** *Ten year follow-up of survival and myocardial infarction in the randomised Coronary Artery Surgery Study.*
Circulation. 1990;82:1629-1646.
-
- Anderson JL, Muhlstein JB, Horne BD, et al.** *Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease.*
Circulation. 2000;102:1227-1232.
-
- Anderson WD, King SB.** *A review of randomised trials of comparing coronary angioplasty and bypass grafting.*
Curr Opin Cardiol. 1996;11:583-590.
-
- Antiplatelet Trialists' Collaboration.** *Collaborative overview of randomised trials of anti-platelet therapy-1: Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients.*
BMJ. 1995;308:81-106.
-
- Ashley E, Myers J, Froelicher V.** *Exercise testing in clinical medicine.*
Lancet. 2000;356:1592-1597.
-
- Block WJ Jr, Crumpacker EL, Dry TJ, Gage RP.** *Prognosis of angina pectoris: observations in 6882 patients.*
JAMA. 1952;150:259.
-
- Boucher HC, Hengstler P, Schindler C, Guyatt G.** *Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials.*
BMJ. 2000;321:73-77.
-
- Bounous EP, Califf RM, Harrell FE, et al.** *Prognostic value of the simplified Selvester QRS score in patients with coronary artery disease.*
J Am Coll Cardiol. 1988;11:35-41.
-
- Brown KA.** *Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age.*
Circulation. 1991;83:363-381.
-
- Brown KA, Rosman DR, Dave RM.** *Stress nuclear myocardial perfusion imaging versus stress echocardiography: prognostic comparisons.*
Prog Cardiovasc Dis. 2000;43:231-244.
-

Bibliography of One Hundred Key Papers

- Bruce RA, DeRouen T, Peterson DR, et al.** *Noninvasive predictors of sudden cardiac death in men with coronary artery disease. Predictive value of maximal stress testing.* **Am J Cardiol.** 1977;39:833-840.
-
- Califf RM, Mark DB, Harrell FE, et al.** *Importance of clinical measures of ischemia in the prognosis of patients with documented coronary disease.* **J Am Coll Cardiol.** 1988;11:20-26.
-
- Chatzioannou SN, Moore WH, Ford PV, et al.** *Prognostic value of myocardial perfusion imaging in patients with high exercise tolerance.* **Circulation.** 1999;99:867-872.
-
- Dargie HJ, Ford I, Fox KM.** *Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina.* **Eur Heart J.** 1996;17:104-112.
-
- Davies RF, Goldberg DA, Forman S, et al.** *Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.* **Circulation.** 1997;95:2037-2043.
-
- Diamond GA.** *Future imperfect: the limitations of clinical prediction models and the limits of clinical prediction.* **J Am Coll Cardiol.** 1989;14:12A-22A.
-
- Diamond GA, Forrester JS.** *Analysis of probability as an aid in the clinical diagnosis of coronary artery disease.* **N Engl J Med.** 1979;300:1350-1358.
-
- Ellestad MH, Wan MKC.** *Predictive implications of stress testing. Follow-up of 2700 subjects after maximum treadmill testing.* **Circulation.** 1975;51:363-369.
-
- Ernst E, Resch KL.** *Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.* **Ann Int Med.** 1993;118:956-963.
-
- Folland ED, Hartigan PM, Parisi PM.** *Percutaneous transluminal angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. Veterans Affairs ACME investigators.* **J Am Coll Cardiol.** 1997;29:1505-1511.
-
- Forslund L, Hjemdahl P, Held C, et al.** *Prognostic implications of results from exercise testing in patients with chronic stable angina pectoris treated with metoprolol or verapamil. A report from the Angina Prognosis Study In Stockholm (APSIS).* **Eur Heart J.** 2000;21:901-910.
-
- Fox KM, Henderson JR, Bertrand ME, Ferrari R, Remme WJ, Simoons ML.** *The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).* **Eur Heart J.** 1998;(19 suppl J):J52-J55.
-
- Gibbons RJ, Chatterjee K, Daley J, et al.** *ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina).* **J Am Coll Cardiol.** 1999;33:2092-2197.
-



-
- Gibson RS.** *The diagnostic and prognostic value of exercise electrocardiography in asymptomatic subjects and stable symptomatic patients.*
Curr Opin Cardiol. 1991;6:536-546.
-
- Gillum R.** *Trends in acute myocardial infarction and coronary artery disease in the United States.*
J Am Coll Cardiol. 1993;23:7275-7277.
-
- Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD.** *Cholesterol reduction yields clinical benefit. Impact of statin trials.*
Circulation. 1998;97:946-952.
-
- Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifield W.** *A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI).*
N Engl J Med. 1994;331:1037-1043.
-
- Hammermeister KE, DeRouen TA, Dodge HT.** *Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations.*
Circulation. 1979;59:421-430.
-
- Harris PJ, Harrell FE Jr, Lee KL, Behar VS, Rosati RA.** *Survival in medically treated coronary artery disease.*
Circulation. 1979;60:1259-1269.
-
- Havarkate F, Thompson S, Pyke SD, Gallimore JR, Pepys MB.** *Production of C-reactive protein and risk of coronary events in stable and unstable angina.*
Lancet. 1997;349:462-466.
-
- Held C, Hjemdahl P, Eriksson P, Bjorkander I, Forslund L, Rehnqvist N.** *Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina.*
Eur Heart J. 2001;22:62-72.
-
- Hilton TC, Chaitman BR.** *The prognosis in stable and unstable angina.*
Cardiol Clin. 1991;9:27-38.
-
- Hjemdahl P, Eriksson SV, Held C, Rehnqvist N.** *Prognosis of patients with stable angina pectoris on antianginal drug therapy.*
Am J Cardiol. 1996;77:6D-16D.
-
- Hueb WA, Soares PR, Almeida de Oliveira S, et al.** *Five-year follow-up of the Medicine, Angioplasty or Surgery Study (MASS): a prospective trial of medical therapy balloon angioplasty or bypass surgery for single proximal left anterior descending coronary artery stenosis.*
Circulation. 1999;100(suppl 19):II107-II113.
-
- Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzias P, Nihoyannopoulos P.** *Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.*
Circulation. 1999;100:793-798.
-
- Jansson JH, Olofsson BO, Nilsson TK.** *Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease.*
Circulation. 1993;88(pt 1):2030-2034.
-
- Juhan-Vague I, Pyke S, Alessi M, Jespersen J, Haverkate F, Thompson S, on behalf of the ECAT Study Group.** *Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris.*
Circulation. 1996;94:2057-2063.
-

Bibliography of One Hundred Key Papers

- Juul Moller S, Edvardson N, Jahnmatz B, Rosen A, Sorenson S, Omblus R.** *Double-blind trial of aspirin in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial Group.* **Lancet.** 1992;340:1421-1425.
-
- Kannel WB, Abbott RD.** *A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study.* **Am Heart J.** 1986;111:391-397.
-
- Kugiyama K, Ota Y, Takazoe K, et al.** *Circulating levels of secretory type II phospholipase A₂ predict coronary events in patients with coronary artery disease.* **Circulation.** 1999;100:1280-1284.
-
- La Rosa JC, Jiang H, Vupputuri S.** *Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.* **JAMA.** 1999;282:2340-2346.
-
- Libby P.** *Molecular bases of the acute coronary syndromes.* **Circulation.** 1995;91:2844-2850.
-
- Mark DB, Hlatky MA, Harrell FE, Lee KL, Califf RM, Pryor DB.** *Exercise treadmill score for predicting prognosis in coronary disease.* **Ann Int Med.** 1987;106:793-800.
-
- Mark DB, Nelson CL, Califf RM, et al.** *Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty.* **Circulation.** 1994;89:2015-2025.
-
- Mark DB, Shaw L, Harrell FE, et al.** *Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease.* **N Engl J Med.** 1991;325:849-853.
-
- Marwick TH.** *Current status of stress echocardiography for diagnosis and prognostic assessment of coronary artery disease.* **Coron Artery Dis.** 1998;9:411-426.
-
- Mock MB, Rinqvist I, Fisher L, et al, and participants in the Coronary Artery Surgery Study.** *Survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry.* **Circulation.** 1982;66:562-568.
-
- Morris CK, Ueshime K, Kawaguchi T, Hideg A, Froelicher VF.** *The prognostic value of exercise capacity: a review of the literature.* **Am Heart J.** 1991;122:1423-1430.
-
- Mulcahy D, Husain S, Zalos G, et al.** *Ischemia during ambulatory monitoring as a prognostic indicator in patients with stable coronary disease.* **JAMA.** 1997; 277:318-324.
-
- Mulcahy D, Keegan J, Cunningham D, et al.** *Circadian variation of total ischaemic burden and its alteration with anti-anginal agents.* **Lancet.** 1988;2:755-759.
-
- McNeer JF, Margolis JR, Lee K, et al.** *The role of the exercise test in the evaluation of patients for ischemic heart disease.* **Circulation.** 1978;57:64-70.
-



-
- Narins CR, Zareba W, Moss AJ, Goldstein RE, Hall WJ.** *Clinical implications of silent versus symptomatic exercise-induced myocardial ischemia in patients with stable coronary disease.*
J Am Coll Cardiol. 1997;29:756-763.
-
- Negel, E, Luehmkuhl H, Bocksch W, et al.** *Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI. Comparison with dobutamine stress echocardiography.*
Circulation. 1999;99:763-770.
-
- No authors listed.** *Prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Second interim report by the European Coronary Surgery Study Group.*
Lancet. 1980;2:491-495.
-
- No authors listed.** *Eleven-year survival in the Veteran's Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group.*
N Engl J Med. 1984;314:1333-1339.
-
- No authors listed.** *The Beta Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta Blocker Pooling Project Research Group.*
Eur Heart J. 1988;9:8-16.
-
- No authors listed.** *Management of stable angina pectoris. Recommendations of the task force of the European Society of Cardiology.*
Eur Heart J. 1997;18:394-413.
-
- Nygaard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE.** *Plasma homocysteine levels and mortality in patients with coronary artery disease.*
N Engl J Med. 1997;337:230-236.
-
- O'Rourke RA, Brundage BH, Froelicher VF, et al.** *American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease.*
J Am Coll Cardiol. 2000;102:126-140.
-
- Parisi AF.** *Clinical trials of coronary revascularization for chronic stable angina: medical treatment versus coronary revascularization.*
Curr Opin Cardiol. 2000;15:275-280.
-
- Pasternak RC, Grundy SM, Levy D, Thompson SD.** *Task Force III: spectrum of risk factors for coronary heart disease.*
J Am Coll Cardiol. 1996;27:978-990.
-
- Pekkanen J, Linn S, Heiss G, et al.** *Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.*
N Engl J Med. 1990;322:1700-1707.
-
- Pepine CJ.** *Rationale for ACE inhibition as an anti-ischæmic therapy.*
Eur Heart J. 1998;19(suppl G):G34-G40.
-
- Pitt B, Waters D, Brown WV, et al.** *Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin Versus Revascularization Treatment Investigators.*
N Engl J Med. 1999;341:70-76.
-

Bibliography of One Hundred Key Papers

- Pocock SJ, Henderson RA, Rickards AF, et al.** *Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery.*
Lancet. 1995;346:1184-1189.
-
- Podrid P, Graboys T, Lown B.** *Prognosis of medically treated patients with coronary artery disease with profound ST depression during exercise testing.*
N Engl J Med. 1981;305:1111-1116.
-
- Pryor DB, Shaw L, McCants CB, et al.** *Value of the history and physical in identifying patients at increased risk for coronary artery disease.*
Ann Int Med. 1993;118:81-90.
-
- Pyorala K, Laakso M, Uusitupa M.** *Diabetes and atherosclerosis: an epidemiologic view.*
Diabetes Metab Rev. 1987;3:463-524.
-
- Regenfus M, Ropers N, Achenbach S, et al.** *Noninvasive detection of coronary artery stenosis using contrast-enhanced three-dimensional breath-hold magnetic resonance coronary angiography.*
J Am Coll Cardiol. 2000;36:44-50.
-
- Rehnqvist N, Hjemdahl P, Billing E, et al.** *Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm.*
Eur Heart J. 1996;17:76-81.
-
- Ridker PM.** *Fibrinolytic and inflammatory markers for arterial occlusion: the evolving epidemiology of thrombosis and hemostasis.*
Thromb Haemost. 1997;78:53-59.
-
- Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E.** *Long-term effects of pravastatin on plasma concentration of C-reactive protein.*
Circulation. 1999;100:230-235.
-
- RITA Trialists.** *Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial.*
Lancet. 1993;341:573-580.
-
- Ross R.** *The pathogenesis of atherosclerosis: a perspective for the 1990s.*
Nature. 1993;362:801-808.
-
- Saitoh T, Kishida H, Tsukada Y, et al.** *Clinical significance of increased plasma concentration of macrophage colony-stimulating factor in patients with angina pectoris.*
J Am Coll Cardiol. 2000;35:655-665.
-
- Scandinavian Simvastatin Survival Study Group.** *Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).*
Lancet. 1994;344:1383-1389.
-
- Shaw LJ, Hachanovitch R, Heller GV, et al.** *Noninvasive strategies for the estimation of cardiac risk in stable chest pain patients. Economics of Noninvasive Diagnosis (END) Study Group.*
Am J Cardiol. 2000;86:1-7.
-
- Shaw LJ, Peterson ED, Shaw LK, et al.** *Use of a prognostic treadmill score in identifying diagnostic coronary artery disease subgroups.*
Circulation. 1998;98:1622-1630.
-



-
- Sievers B, Hamm CW, Herzner A, Kuck KH.** *Medical therapy versus PTCA: a prospective, randomized trial in patients with asymptomatic coronary single vessel disease.*
Circulation. 1993;93(suppl I):I297. Abstract.
-
- Simoons ML, Vos J, de Feyter, et al.** *EUROPA substudies, confirmation of pathophysiological concepts.*
Eur Heart J. 1998;19:(suppl J):J56-J70.
-
- Snader CE, Marwick TH, Pashkow FJ, Harvey SA, Thomas JD, Lauer MS.** *Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: report of 3400 patients from a single center.*
J Am Coll Cardiol. 1997;30:641-648.
-
- Sullivan JM, Van der Zwaag RV, el-Zeky F, Ramanathan KB, Mirvis DM.** *Left ventricular hypertrophy: effect on survival.*
J Am Coll Cardiol. 1993;22:508-513.
-
- Takaro T.** *Results of a randomized study of medical and surgical management of angina pectoris.*
World J Surg. 1978;2:797-807.
-
- Tervahatuta M, Pekkanen J, Nissinen A.** *Risk factors of coronary heart disease and total mortality among elderly men with and without preexisting coronary heart disease. Finnish Cohorts of the Seven Countries Study.*
J Am Coll Cardiol. 1995;26:1626-1629.
-
- Thadani U.** *Treatment of stable angina.*
Curr Opin Cardiol. 1999;14:349-358.
-
- Thompson C, Jabbour S, Goldberg R, et al.** *Exercise performance-based outcomes of medically treated patients with coronary artery disease and profound ST depression.*
J Am Coll Cardiol. 2000;36:2140-2145.
-
- Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC.** *Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.*
N Engl J Med. 1995;332:635-641.
-
- Usher BW, O'Brien TX.** *Recent advances in dobutamine stress echocardiography.*
Clin Cardiol. 2000;23:560-570.
-
- Vaughan CJ, Murphy MB, Buckley B.** *Statins do more than just lower cholesterol.*
Lancet. 1996;348:1079-1082.
-
- Varnauskas E.** *Twelve-year follow-up of survival in the randomized European Coronary Surgery Study.*
N Engl J Med. 1988;319:332-337.
-
- Wallen NH, Held C, Rehnqvist N, Hjemdahl P.** *Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction.*
Eur Heart J. 1999;20:1039-1043.
-
- Weiner DA, McCabe CH, Ryan TJ.** *Prognostic assessment of patients with coronary artery disease by exercise testing.*
Am Heart J. 1983;105:749-755.
-

Bibliography of One Hundred Key Papers

Weiner DA, Ryan TJ, McCabe CH, et al.

Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease.

J Am Coll Cardiol. 1984;3:772-779.

Weiner DA, Ryan TJ, Parsons L, et al.

Long-term prognostic value of exercise testing in men and women from the Coronary Artery Surgery Study (CASS) Registry.

Am J Cardiol. 1995;75:865-870.

Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators.

Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial.

JAMA. 1997;277:715-721.

Wyns W, Musschaert-Beauthier E, Van Domburg R, et al.

Prognostic value of symptom limited exercise testing in men with a high prevalence of coronary artery disease

Eur Heart J. 1985;6:939-945.

Yusuf S, Zucker D, Peduzzi P, et al.

Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomized trials of the Coronary Artery Bypass Graft Surgery Trialists Collaboration.

Lancet. 1994;344:563-570.

Zaret BL, Wackers FJ.

Nuclear cardiology. Part 1.

N Engl J Med. 1993;329:775-783.

Zaret BL, Wackers FJ.

Nuclear cardiology. Part 2.

N Engl J Med. 1993;329:855-861.

Zellweger MJ, Lewin HC, Lai S, et al.

When to stress patients after coronary artery surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies.

J Am Coll Cardiol. 2001;37:144-152.

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in **English**. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), short running title, keywords, and acknowledgments, as well as full names (first name, middle name(s), and last name) with highest academic degrees (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—hard copies and on disk, where possible) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All illustrations should be cited in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Systeme International (SI)** units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and numbered consecutively using superscript arabic numerals. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the bibliography, titles of journals should be abbreviated according to the Index Medicus. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals “the Vancouver style.* Ann Intern Med. 1997;126:36-47). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg.* 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation.* 1977;56(suppl II):II161-II164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza.* Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting:** all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher's editorial dept according to the specifications of the current edition of the **American Medical Association Manual of Style, Williams & Wilkins**. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial dept will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial dept and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.

- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction of existing work, it is the author's responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

EDITORIAL

The editorial should not exceed 2 standard typed pages (maximum 600 words).

LEAD ARTICLE

The lead article should not exceed 25 standard typed pages (maximum 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of **10 references of “seminal papers”** as well as a separate list of **100 Key References** should be provided.

RESPONDENT ARTICLES

Respondent articles should not exceed 25 standard typed pages (maximum 2500 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.